https://scholars.lib.ntu.edu.tw/handle/123456789/568543
標題: | Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma | 作者: | Yeo W. PEI-JER CHEN Furuse J. Han K.-H. CHIUN HSU Lim H.-Y. Moon H. Qin S. Yeoh E.-M. Ye S.-L. |
公開日期: | 2010 | 出版社: | BioMed Central Ltd. | 卷: | 10 | 起(迄)頁: | 620 | 來源出版物: | BMC Cancer | 摘要: | The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection. Improved survival with sorafenib has fostered new research but many challenges remain in designing clinical trials. The disease, its management, and populations affected by it are heterogeneous worldwide and within Asia. An expert conference of Eastern Asian oncologists and hepatologists was convened to foster consensus in clinical trial design. The panel identified key areas that need to be addressed to facilitate clinical trials in Asia. Stratification by viral etiology is desirable within Asia and by region in global trials. Antiviral therapy should also be considered as a stratification factor and incorporated into HCC management in trials. The panel agreed that histological diagnosis is not required for trial entry and that Barcelona-Clinic Liver Cancer (BCLC) staging is acceptable for trials as long as portal hypertension can be better defined with standardized methodology. Consensus in treatment must be sought to allow multi-national trials and it must be recognized that first-line sorafenib is not largely feasible in Asia. Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease.? 2010 Yeo et al; licensee BioMed Central Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-78149265063&doi=10.1186%2f1471-2407-10-620&partnerID=40&md5=742e4d399619d0251c81f9006b6bbcb6 https://scholars.lib.ntu.edu.tw/handle/123456789/568543 |
ISSN: | 1471-2407 | DOI: | 10.1186/1471-2407-10-620 | SDG/關鍵字: | 1 [4 (3 amino 1h indazol 4 yl)phenyl] 3 (2 fluoro 5 methylphenyl)urea; antivirus agent; ave 1642; bevacizumab; bortezomib; brivanib; capecitabine; celecoxib; cisplatin; cytotoxic agent; docetaxel; doxorubicin; epirubicin; erlotinib; everolimus; fluorouracil; gemcitabine; interferon; lamivudine; mitomycin C; oxaliplatin; pazopanib; pi 88; placebo; sorafenib; sunitinib; thalidomide; UFT; unindexed drug; vandetanib; antiviral therapy; article; artificial embolism; Asian; bleeding disorder; cancer staging; Chinese medicine; clinical study; clinical trial; consensus development; continuous infusion; diarrhea; drug megadose; fatigue; feasibility study; foot disease; hand disease; heart left ventricle failure; hepatitis B; hepatitis C; Hepatitis C virus; human; hyponatremia; liver cell carcinoma; liver function test; low drug dose; medical expert; molecularly targeted therapy; neutropenia; portal hypertension; side effect; skin toxicity; thrombocytopenia; treatment planning; unspecified side effect; Asia; clinical trial (topic); liver cell carcinoma; liver tumor; methodology; oncology; Asia; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Medical Oncology; Molecular Targeted Therapy; Neoplasm Staging; Research Design |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。